AsiaNet 87438

STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire=KYODO JBN/ --

Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce

that they have entered an agreement under which WinHealth gains the exclusive

commercial rights to Ravicti(R) (glycerol phenylbutyrate), in a territory

covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia,

Malaysia, Philippines and Thailand.

Ravicti(R) is in Europe and North America indicated for treatment of urea cycle

disorders (UCD), and under the announced partnership, WinHealth is granted a

license to register and commercialize the product in UCD in the countries of

the specified territory.

"It is with great pleasure that we announce this partnership with WinHealth,

under which we will be able to make Ravicti(R) available to UCD patients also

in this part of the world. It also strengthens Immedica's geographical

footprint, by introducing yet another rare disease collaboration to our

network", says Anders Edvell, CEO of Immedica.

Torreya acted as a financial advisor to Immedica for this transaction.

Jack Wang, Chairman and CEO of Winhealth, comments, "Urea Cycle Disorder

represents a severely underserved medical need in China, resulting in severe

neurocognitive decline, coma or even death, if left untreated. We are very

excited to partner up with Immedica and look forward to bringing Ravicti®, an

innovative therapeutic approved both in Europe and the United States, to the

patients suffering from UCD in China and adjacent countries."

About Urea Cycle Disorders (UCD)

The urea cycle is a process in which waste (ammonia) is removed from the body.

Several inherited conditions can cause problems with this waste-removal

process. People with a urea cycle disorder are missing a gene that makes the

enzymes needed to break down ammonia in the body. As a group, these disorders

occur in 1 in 30,000 newborns in the territories where Immedica has acquired

rights.

Typically, symptoms such as confusion, nausea, vomiting, decreased food intake

and increased sleepiness occur within the first week after birth.

About Immedica

Immedica is a fast-growing private European niche pharma group. Its headquarter

is based in Stockholm, Sweden, and the company has direct pan-European and

Middle East commercial coverage. In addition, Immedica provides some of its

products to other parts of the world via a network of regional partners.

Immedica provides significant know-how and experience from commercialization of

niche/specialty care products across Europe and the Middle East, and the

company's management team has an outstanding track record of partnering and

operating niche pharma products internationally. Immedica has capabilities to

provide optimal access of specialty care medicines to patients with significant

medical needs, including key areas such as regulatory affairs,

pharmacovigilance, medical affairs, pricing & reimbursement, and product

distribution.

About WinHealth

WinHealth Pharma is a commercial-stage biopharmaceutical company aiming at

fulfilling severely unmet or underserved medical needs for patients with rare

diseases and other critical medical conditions in China and surrounding

regions. Since its inception, WinHealth has been committed to sourcing,

developing, and commercializing innovative therapies from leading biotech and

pharmaceutical companies worldwide. Winhealth has established long-term

strategic partnerships with a variety of leading international firms and

successfully built a diversified pipeline consisting of both clinical-stage and

commercial-stage products. In addition to its strong development and regulatory

capabilities, WinHealth has established an industry-leading commercial

infrastructure covering China and adjacent markets, providing patients with

faster access to novel therapeutics globally.

Contacts

WinHealth Pharma Group CO., Ltd.

Oliver Hao – CO-CEO

oliver.hao@winhealth.hk  

Phone: +86 18602108327

SOURCE:  Winhealth Pharma Group HK